2015 World STI & HIV Congress and Australasian HIV&AIDS Conference

Robert (Bob) Grant has 30 years of experience with HIV/AIDS research and clinical care, including 15 years of experience with studies of post- and pre-exposure prophylaxis. He is a Senior Investigator at the Gladstone Institute of Virology and Immunology and a Professor of Medicine at the University of California San Francisco. 

Dr. Grant served as protocol chair for the iPrEx trial, called “Chemoprophylaxis for HIV Prevention in Men,” which was funded as an NIH UO1 and by a grant from the Bill and Melinda Gates Foundation, the NIH-funded open-label roll-over iPrEx OLE, and HPTN 067, called the ADAPT study (Alternative Dosing to Augment PrEP Tablet use). He was also a co-investigator for the FEM-PREP trial, the CDC-sponsored safety study of PrEP safety in US MSM, and the West African PrEP study. 

Dr. Grant served on the PrEP trialists working group, and has acted as an advisor to the WHO, UNAIDS, CDC, and Gilead, regarding the prevention use of antiretroviral therapy. Currently, he works part time as the Chief Medical Officer for the San Francisco AIDS Foundation. In 2012, Dr. Grant was honored to be on the TIME 100 list of The Most Influential People in the World.